Trial Profile

Effects of supratherapeutic doses of aleglitazar on QT prolongation.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Dec 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aleglitazar; Moxifloxacin
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Roche

Most Recent Events

27 Dec 2011 New trial record
21 Nov 2011 Results published in the Journal of Cardiovascular Pharmacology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com